Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 534-539

  Gardner, Thomas A ^a   Elzey, Bennett D ^b   Hahn, Noah M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APC8015; CD54; Dendritic cells; GM CSF; PA2024; Prostatic acid phosphatase; Therapeutic vaccine

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ACID PHOSPHATASE PROSTATE ISOENZYME; BICALUTAMIDE; CABAZITAXEL; CANCER VACCINE; CHIMERIC PROTEIN; CORTICOSTEROID; DEGARELIX; FLUTAMIDE; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; NILUTAMIDE; PA 2024; PAP 2024; PLACEBO; PREDNISONE; SIPULEUCEL T; TRIPTORELIN; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; TISSUE EXTRACT;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTHRALGIA; ASYMPTOMATIC DISEASE; BACKACHE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL SURFACE; CELLULAR IMMUNITY; CHILL; DISEASE SEVERITY; DRUG APPROVAL; DRUG SAFETY; EX VIVO STUDY; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNOCOMPETENT CELL; INFUSION; LEUKAPHERESIS; LIVER FUNCTION TEST; METASTASIS; MYALGIA; NAUSEA; NONHUMAN; PAIN; PATIENT CARE; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SURVIVAL TIME; DRUG TOXICITY; IMMUNOTHERAPY; MALE; METHODOLOGY; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

CANCER VACCINES; DRUG TOXICITY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TISSUE EXTRACTS; TREATMENT OUTCOME; UNITED STATES;

EID: 84860713852     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19795     Document Type: Review

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516.
3. Pound CR, Brawer MK, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001; 3:72-84; PMID:16985694.
4. Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, et al. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 1986; 76:179-85; PMID:2418245.
5. Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 2011; 40:655-71; PMID:21889727; http://dx.doi.org/10.1016/j.ecl.2011.05.004.
6. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151:622-8; PMID:8308972.
7. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159:3113-7; PMID:9317107.
8. low/- monocytes in prostate cancer. Prostate 2010; 70:443-55; PMID:19902470.
9. Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: a review. J Clin Pathol 1981; 34:1343-8; PMID:7035499; http://dx.doi.org/10.1136/jcp.34.12. 1343.
10. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997; 12:807-12; PMID:9225164.
11. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189:487-95; PMID:10629548; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4〈487:: AIDPATH484〉3.0.CO;2-I.
12. Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002; 41:152-7; PMID:12147093; http://dx.doi.org/10.1046/j.1365-2559.2002.01437.x.
13. Ownby HE, Roi LD, Isenberg RR, Brennan MJ. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983; 52:126-30; PMID:6850535; http://dx.doi.org/10.1002/1097-0142(19830701)52: 1〈126::AIDCNCR2820520123〉3.0.CO;2-Y.
14. Goldsmith MM, Belchis DA, Cresson DH, Merritt WD, 3rd, Askin FB. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 1992; 106:27-33; PMID:1734363.
15. Dalal BI, Das KC, Dutta TK, Malakar K. Local and systemic eosinophilia in patients with carcinoma of the uterine cervix undergoing radiation therapy: correlation with radiation response. Clinical oncology (Royal College of Radiologists (Great Britain)) 1992; 4:18-21.
16. Bethwaite PB, Holloway LJ, Yeong ML, Thornton A. Effect of tumour associated tissue eosinophilia on survival of women with stage IB carcinoma of the uterine cervix. J Clin Pathol 1993; 46:1016-20; PMID:8254087; http://dx.doi.org/10.1136/jcp.46.11.1016.
17. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003; 197:387-93; PMID:12566422; http://dx.doi.org/10.1084/jem.20021683.
18. van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991; 78:1538-44; PMID:1884020.
19. Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175-82; PMID:10873066.
20. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60:197-204; PMID:15176049; http://dx.doi.org/10. 1002/pros.20040.
21. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318.
22. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID:16809734; http://dx.doi.org/10.1200/JCO.2005.04.5252.
23. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
24. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:273-9; PMID:22232132; http://dx.doi.org/10.1093/jnci/ djr514.
25. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al.; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-46; PMID:20398925; http://dx.doi.org/10.1016/S0140-6736(10)60172-9.
26. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-90; PMID:19359544; http://dx.doi.org/10.1126/science. 1168175.
27. Pal SK, Sartor O. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2011; 68:103-5; PMID:21093995; http://dx.doi.org/10.1016/j.maturitas.2010.10.009.
28. Martin JM, Supiot S, Berthold DR. Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs 2011; 71:1019-41; PMID:21668040; http://dx.doi.org/10.2165/11591500-000000000-00000.